# Jiangsu Hansoh Pharmaceutical Co., Ltd.: Phase 1 study in Hepatic Impairment (Moderate or Mild) & Normal Hepatic Function (32 participants)

**Score:** 40/100

| Field | Value |
|---|---|
| Sponsor | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of HS-10506 |
| NCT ID | NCT07844967 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Hepatic Impairment (Moderate or Mild) & Normal Hepatic Function |
| Intervention types | drug |
| Target enrollment | 32 |
| Site countries | China |
| Posted | 2026-09-28 |
| Planned start | 2026-06-01 |
| Event | Newly registered study |
| Event date | 2026-09-28 |

## Why this score
- Industry sponsor (buys outsourced services).

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07844967). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.